Molecular imaging and neural networks in impulse control disorders in Parkinson’s disease
Identifieur interne : 000642 ( Main/Exploration ); précédent : 000641; suivant : 000643Molecular imaging and neural networks in impulse control disorders in Parkinson’s disease
Auteurs : I. Aracil-Bola Os [Canada] ; A. P. Strafella [Canada]Source :
- Parkinsonism & related disorders [ 1353-8020 ] ; 2015.
English descriptors
- KwdEn :
- Animals, Corpus Striatum (metabolism), Corpus Striatum (pathology), Disruptive, Impulse Control, and Conduct Disorders (chemically induced), Disruptive, Impulse Control, and Conduct Disorders (diagnosis), Disruptive, Impulse Control, and Conduct Disorders (metabolism), Dopamine (metabolism), Dopamine Agonists (adverse effects), Humans, Molecular Imaging (methods), Nerve Net (metabolism), Nerve Net (pathology), Neuroimaging (methods), Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease (metabolism).
- MESH :
- chemical , adverse effects : Dopamine Agonists.
- chemical , metabolism : Dopamine.
- chemically induced : Disruptive, Impulse Control, and Conduct Disorders.
- diagnosis : Disruptive, Impulse Control, and Conduct Disorders, Parkinson Disease.
- drug therapy : Parkinson Disease.
- metabolism : Corpus Striatum, Disruptive, Impulse Control, and Conduct Disorders, Nerve Net, Parkinson Disease.
- methods : Molecular Imaging, Neuroimaging.
- pathology : Corpus Striatum, Nerve Net.
- Animals, Humans.
Abstract
Impulse control disorders (ICDs) may arise in Parkinson’s disease (PD) in relation to the use of dopamine agonists (DA). A dysfunction of reward circuits is considered the main underlying mechanism. Neuroimaging has been largely used in this setting to understand the structure of the reward system and its abnormalities brought by exogenous stimulation in PD. Dopaminergic changes, such as increased dopamine release, reduced dopamine transporter activity and other changes, have been shown to be a consistent feature of ICDs in PD. Beyond the striatum, alterations of prefrontal cortical function may also impact an individuals’ propensity for impulsivity. Neuroimaging is advancing our knowledge of the mechanisms involved in the development of these behavioral addictions. An increased understanding of these disorders may lead to the discovery of new therapeutic targets, or the identification of risk factors for the development of these disorders.
Url:
DOI: 10.1016/j.parkreldis.2015.08.003
PubMed: 26298389
PubMed Central: 4874782
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000902
- to stream Pmc, to step Curation: 000902
- to stream Pmc, to step Checkpoint: 000262
- to stream PubMed, to step Corpus: 000345
- to stream PubMed, to step Curation: 000345
- to stream PubMed, to step Checkpoint: 000345
- to stream Ncbi, to step Merge: 001C85
- to stream Ncbi, to step Curation: 001C85
- to stream Ncbi, to step Checkpoint: 001C85
- to stream Main, to step Merge: 000643
- to stream Main, to step Curation: 000642
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Molecular imaging and neural networks in impulse control disorders in Parkinson’s disease</title><author><name sortKey="Aracil Bola Os, I" sort="Aracil Bola Os, I" uniqKey="Aracil Bola Os I" first="I." last="Aracil-Bola Os">I. Aracil-Bola Os</name><affiliation wicri:level="4"><nlm:aff id="A1">Morton and Gloria Shulman Movement Disorder Unit & Edmond J. Safra Program in Parkinson Disease, Toronto Western Hospital, UHN, University of Toronto, Ontario, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Morton and Gloria Shulman Movement Disorder Unit & Edmond J. Safra Program in Parkinson Disease, Toronto Western Hospital, UHN, University of Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="4"><nlm:aff id="A2">Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="4"><nlm:aff id="A3">Division of Brain, Imaging and Behaviour – Systems Neuroscience, Toronto Western Research Institute, UHN, University of Toronto, Ontario, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Brain, Imaging and Behaviour – Systems Neuroscience, Toronto Western Research Institute, UHN, University of Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Strafella, A P" sort="Strafella, A P" uniqKey="Strafella A" first="A. P." last="Strafella">A. P. Strafella</name><affiliation wicri:level="4"><nlm:aff id="A1">Morton and Gloria Shulman Movement Disorder Unit & Edmond J. Safra Program in Parkinson Disease, Toronto Western Hospital, UHN, University of Toronto, Ontario, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Morton and Gloria Shulman Movement Disorder Unit & Edmond J. Safra Program in Parkinson Disease, Toronto Western Hospital, UHN, University of Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="4"><nlm:aff id="A2">Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="4"><nlm:aff id="A3">Division of Brain, Imaging and Behaviour – Systems Neuroscience, Toronto Western Research Institute, UHN, University of Toronto, Ontario, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Brain, Imaging and Behaviour – Systems Neuroscience, Toronto Western Research Institute, UHN, University of Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">26298389</idno><idno type="pmc">4874782</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874782</idno><idno type="RBID">PMC:4874782</idno><idno type="doi">10.1016/j.parkreldis.2015.08.003</idno><date when="2015">2015</date><idno type="wicri:Area/Pmc/Corpus">000902</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000902</idno><idno type="wicri:Area/Pmc/Curation">000902</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000902</idno><idno type="wicri:Area/Pmc/Checkpoint">000262</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000262</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">000345</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000345</idno><idno type="wicri:Area/PubMed/Curation">000345</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000345</idno><idno type="wicri:Area/PubMed/Checkpoint">000345</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000345</idno><idno type="wicri:Area/Ncbi/Merge">001C85</idno><idno type="wicri:Area/Ncbi/Curation">001C85</idno><idno type="wicri:Area/Ncbi/Checkpoint">001C85</idno><idno type="wicri:doubleKey">1353-8020:2015:Aracil Bola Os I:molecular:imaging:and</idno><idno type="wicri:Area/Main/Merge">000643</idno><idno type="wicri:Area/Main/Curation">000642</idno><idno type="wicri:Area/Main/Exploration">000642</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Molecular imaging and neural networks in impulse control disorders in Parkinson’s disease</title><author><name sortKey="Aracil Bola Os, I" sort="Aracil Bola Os, I" uniqKey="Aracil Bola Os I" first="I." last="Aracil-Bola Os">I. Aracil-Bola Os</name><affiliation wicri:level="4"><nlm:aff id="A1">Morton and Gloria Shulman Movement Disorder Unit & Edmond J. Safra Program in Parkinson Disease, Toronto Western Hospital, UHN, University of Toronto, Ontario, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Morton and Gloria Shulman Movement Disorder Unit & Edmond J. Safra Program in Parkinson Disease, Toronto Western Hospital, UHN, University of Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="4"><nlm:aff id="A2">Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="4"><nlm:aff id="A3">Division of Brain, Imaging and Behaviour – Systems Neuroscience, Toronto Western Research Institute, UHN, University of Toronto, Ontario, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Brain, Imaging and Behaviour – Systems Neuroscience, Toronto Western Research Institute, UHN, University of Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Strafella, A P" sort="Strafella, A P" uniqKey="Strafella A" first="A. P." last="Strafella">A. P. Strafella</name><affiliation wicri:level="4"><nlm:aff id="A1">Morton and Gloria Shulman Movement Disorder Unit & Edmond J. Safra Program in Parkinson Disease, Toronto Western Hospital, UHN, University of Toronto, Ontario, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Morton and Gloria Shulman Movement Disorder Unit & Edmond J. Safra Program in Parkinson Disease, Toronto Western Hospital, UHN, University of Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="4"><nlm:aff id="A2">Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="4"><nlm:aff id="A3">Division of Brain, Imaging and Behaviour – Systems Neuroscience, Toronto Western Research Institute, UHN, University of Toronto, Ontario, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Brain, Imaging and Behaviour – Systems Neuroscience, Toronto Western Research Institute, UHN, University of Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author></analytic><series><title level="j">Parkinsonism & related disorders</title><idno type="ISSN">1353-8020</idno><idno type="eISSN">1873-5126</idno><imprint><date when="2015">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Corpus Striatum (metabolism)</term><term>Corpus Striatum (pathology)</term><term>Disruptive, Impulse Control, and Conduct Disorders (chemically induced)</term><term>Disruptive, Impulse Control, and Conduct Disorders (diagnosis)</term><term>Disruptive, Impulse Control, and Conduct Disorders (metabolism)</term><term>Dopamine (metabolism)</term><term>Dopamine Agonists (adverse effects)</term><term>Humans</term><term>Molecular Imaging (methods)</term><term>Nerve Net (metabolism)</term><term>Nerve Net (pathology)</term><term>Neuroimaging (methods)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Disruptive, Impulse Control, and Conduct Disorders</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Disruptive, Impulse Control, and Conduct Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term><term>Disruptive, Impulse Control, and Conduct Disorders</term><term>Nerve Net</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Molecular Imaging</term><term>Neuroimaging</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Corpus Striatum</term><term>Nerve Net</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">Impulse control disorders (ICDs) may arise in Parkinson’s disease (PD) in relation to the use of dopamine agonists (DA). A dysfunction of reward circuits is considered the main underlying mechanism. Neuroimaging has been largely used in this setting to understand the structure of the reward system and its abnormalities brought by exogenous stimulation in PD. Dopaminergic changes, such as increased dopamine release, reduced dopamine transporter activity and other changes, have been shown to be a consistent feature of ICDs in PD. Beyond the striatum, alterations of prefrontal cortical function may also impact an individuals’ propensity for impulsivity. Neuroimaging is advancing our knowledge of the mechanisms involved in the development of these behavioral addictions. An increased understanding of these disorders may lead to the discovery of new therapeutic targets, or the identification of risk factors for the development of these disorders.</p></div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="Canada"><region name="Ontario"><name sortKey="Aracil Bola Os, I" sort="Aracil Bola Os, I" uniqKey="Aracil Bola Os I" first="I." last="Aracil-Bola Os">I. Aracil-Bola Os</name></region><name sortKey="Aracil Bola Os, I" sort="Aracil Bola Os, I" uniqKey="Aracil Bola Os I" first="I." last="Aracil-Bola Os">I. Aracil-Bola Os</name><name sortKey="Aracil Bola Os, I" sort="Aracil Bola Os, I" uniqKey="Aracil Bola Os I" first="I." last="Aracil-Bola Os">I. Aracil-Bola Os</name><name sortKey="Strafella, A P" sort="Strafella, A P" uniqKey="Strafella A" first="A. P." last="Strafella">A. P. Strafella</name><name sortKey="Strafella, A P" sort="Strafella, A P" uniqKey="Strafella A" first="A. P." last="Strafella">A. P. Strafella</name><name sortKey="Strafella, A P" sort="Strafella, A P" uniqKey="Strafella A" first="A. P." last="Strafella">A. P. Strafella</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000642 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000642 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:4874782
|texte= Molecular imaging and neural networks in impulse control disorders in Parkinson’s disease
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26298389" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |